論文・技術情報追加のお知らせ

1. Dextromethorphan-bupropion-associated pharmacovigilance signals based on the FAERS database: An observational study.

デキストロメトルファン・ブプロピオンの副作用をFAERSで解析。

対象DB：FAERS

2. Pregnancy-related adverse events and congenital disorders associated with aspirin: A real-world pharmacovigilance analysis of the FDA adverse event reporting system.

アスピリン使用に伴う妊娠合併症・先天性障害のFAERS解析。

対象DB：FAERS

3. Comprehensive pharmacovigilance assessment of pairwise drug-drug interactions and acute pancreatitis in the FDA adverse event reporting system: focus on incretin-based drugs.

インクレチン薬と他剤の併用による急性膵炎リスクの解析。

対象DB：FAERS

4. Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event reporting system.

性ホルモン感受性固形がん治療薬による間質性肺疾患の解析。

対象DB：FAERS

5. A real-world pharmacovigilance study of romidepsin based on FDA adverse event reporting system database.

ロミデプシンの安全性をFAERSデータに基づきリアルワールド解析。

対象DB：FAERS

6. Post-marketing safety of tarlatamab in small cell lung cancer based on FAERS and WHO-VigiAccess with SHAP-based interpretable machine learning analysis of immune-related adverse events.

タルラタマブの市販後安全性をFAERS等のデータで評価。

対象DB：FAERS

7. Post-marketing safety evaluation of anthracycline for acute myeloid leukemia treatment: a real-world pharmacovigilance analysis.

急性骨髄性白血病へのアントラサイクリンの市販後安全性。

対象DB：FAERS

8. Psychiatric Safety Signals of GLP-1 Receptor Agonists: A FAERS-Based Pharmacovigilance Study with Explainable Machine Learning.

GLP-1受容体作動薬の精神的副作用シグナルを機械学習で解析。

対象DB：FAERS,KAERS

9. An Updated 16-Year Pharmacovigilance Analysis of Neuropsychiatric Safety Profiles of Ciprofloxacin, Levofloxacin, and Moxifloxacin Using FAERS Data.

キノロン系薬3種の精神神経副作用プロファイルを16年間解析。

対象DB：FAERS

10. Prioritizing Antidiabetic Drugs for Inflammatory Bowel Disease Through Inverse Signal Detection: A FAERS Pharmacovigilance Study.

逆シグナル検出を用い炎症性腸疾患に有用な糖尿病薬を特定。

対象DB：FAERS

11. Post-Marketing Safety of mRNA Vaccines: A Real-World Study Integrating Literature Case Reports and Vaccine Adverse Event Reporting System.

症例報告とVAERSの統合によるmRNAワクチンの市販後調査。

対象DB：FAERS,VAERS

12. Safety of belimumab during pregnancy: associations with maternal and fetal or newborn adverse outcomes based on FAERS data.

妊娠中のベリムマブ使用に伴う母体・胎児の不良転帰リスク。

対象DB：FAERS

13. Mirtazapine identified as a preventive agent against cisplatin-induced nephrotoxicity: Integrating in silico, in vitro, and in vivo analyses.

ミルタザピンのシスプラチン腎毒性軽減効果を統合的に検証。

対象DB：FAERS

14. Cardiac arrhythmias following COVID-19 vaccination: insights from the U.S. vaccine adverse event reporting system (VAERS), December 2020-January 2025, United States.

COVID-19ワクチン接種後の心拍不整脈をVAERSで解析。

対象DB：FAERS,VAERS

15. Early prediction and risk assessment of adverse drug combinations using ensemble learning.

アンサンブル学習を用いた有害な薬剤併用パターンの早期予測。

対象DB：FAERS

16. Association between rivaroxaban use and acute kidney injury in patients over 65 years: A large-scale analysis of spontaneous reporting system data.

65歳以上の高齢者でのリバロキサバン使用と急性腎障害の関連。

対象DB：FAERS

17. Potential oral and maxillofacial adverse events associated with glucagon-like peptide-1 receptor agonist administration: a narrative review.

GLP-1受容体作動薬投与に伴う潜在的口腔・顎顔面副作用。

対象DB：FAERS

18. PCSK9 inhibitors do not increase cognitive risk.

PCSK9阻害薬は認知機能障害のリスクを増加させない。

対象DB：FAERS

19. Comparative post-marketing reporting signals of elagolix and myfembree in endometriosis: a FAERS pharmacovigilance study.

子宮内膜症治療薬エラゴリクスとマイフェンブリーの副作用比較。

対象DB：FAERS

20. Hand-foot skin reaction associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a FAERS-based pharmacovigilance study.

VEGFR-TKIに伴う手足皮膚反応のFAERS不均衡解析。

対象DB：FAERS

21. Risk of drug-related aggression in pediatric populations: a pharmacovigilance analysis using the FAERS database.

小児における薬剤関連攻撃性のリスクをFAERSデータで解析。

対象DB：FAERS

22. Coagulation dysfunction events associated with novel tetracycline-class drugs: a disproportionality and Bayesian analysis based on the FAERS database.

新規テトラサイクリン系薬による凝固機能障害イベントの解析。

対象DB：FAERS

23. Comparative Real-World Safety Profiles of Fibroblast Growth Factor Receptor Inhibitors: A Pharmacovigilance Study.

FGFR阻害薬間におけるリアルワールドの安全性プロファイル比較。

対象DB：FAERS

24. Possible clinical drug interactions between ticagrelor and concomitant medications: for adverse drug event monitoring in real-world.

チカグレロルと併用薬の潜在的な臨床的相互作用の監視。

対象DB：FAERS

25. A comprehensive study on drug-related dysphonia: a 20-year disproportionality analysis of the FAERS database.

薬剤性発声障害に関する20年間のFAERSデータ不均衡解析。

対象DB：FAERS

26. Post-marketing safety evaluation of mirogabalin using the JADER database.

ミロガバリンの安全性をJADERデータベースを用いて評価。

対象DB：JADER

27. Pharmacovigilance analysis of cutaneous adverse drug reactions for cetuximab, panitumumab, and necitumumab based on EudraVigilance and WHO VigiAccess.

EGFR阻害薬3種による皮膚副作用のEudraVigilance解析。

対象DB：EudraVigilance

28. Risks Associated with 5alpha-Reductase Inhibitor Use: Analysis of Adverse Drug Reactions Reported to EudraVigilance.

5α還元酵素阻害薬使用に伴う副作用のEudraVigilance解析。

対象DB：EudraVigilance

29. Incretin-Based Drugs for Obesity: Common and Drug-Specific Reporting Patterns of Adverse Drug Reactions-A Comparative Disproportionality Analysis Using EudraVigilance Reports Integrating SmPC Data.

肥満治療用インクレチン薬の共通・薬剤特異的副作用の比較。

対象DB：EudraVigilance

30. Monitoring the safety of the adjuvanted human papillomavirus vaccine HPV-16/18-AS04 in association with pregnancy and potential immune-related diseases in China: A retrospective observational cohort study.

アジュバント添加HPVワクチンの妊娠・出産期の安全性監視。

対象DB：EudraVigilance

31. Prescribing trends and spontaneous reporting patterns of adverse drug reactions of ADHD medications in children and adolescents in germany: A retrospective analysis (2013-2022).

小児・思春期におけるADHD治療薬の処方動向と副作用傾向。

対象DB：EudraVigilance

32. Vonoprazan is associated with a phenotype-specific increase in cholangitis reporting in immune checkpoint inhibitor-treated patients: a VigiBase pharmacovigilance study.

ICI治療患者でのボノプラザン使用に伴う胆管炎報告の増加。

対象DB：VigiBase

33. Effect of Deuterated Drugs on Safety: Insights from Pharmacovigilance Data Analysis.

重水素化薬剤が安全性に与える影響の副作用データ分析。

対象DB：VigiBase

34. Should nintedanib be continued after acute exacerbation of idiopathic pulmonary fibrosis? A retrospective observational study using a nationwide database in Japan.

特発性肺線維症の急性増悪後におけるニンテダニブ継続の是非。

対象DB：DPC

35. Trends and determinants of acute tocolysis implementation in Japan, 2012-2023: An 11-year nationwide retrospective cohort study.

日本における急性切迫流早産治療（子宮収縮抑制）の動向。

対象DB：DPC

36. Maternal Complications and Facility-Level Differences in the Management of Placental Abruption in Japan: A Retrospective Analysis Using a Multicenter DPC Database.

日本における常位胎盤早期剥離管理の母体合併症と施設間差。

対象DB：DPC

37. Predicting the risk of serious muscle disorders in individuals eligible for statin treatment in England: derivation and validation of a clinical prediction model.

英国でのスタチン治療対象者における重篤な筋障害リスク予測。

対象DB：CPRD

38. Performance of multivariable risk prediction algorithms in predicting COPD exacerbations: a population-based study.

COPD急性増悪を予測する多変数リスク予測アルゴリズムの性能。

対象DB：CPRD

39. Primary care use among adults with eating disorders in England: a population-based cohort study using electronic health records.

英国の摂食障害成人におけるプライマリケア利用に関するコホート。

対象DB：CPRD

40. Migraine diagnosis and management in children and adolescents: a primary care study in England.

英国の子供・思春期における偏頭痛の診断と管理の実態調査。

対象DB：CPRD

41. Prescription cascades associated with acetylcholinesterase inhibitors use: a high-throughput sequence symmetry analysis.

アセチルコリンエステラーゼ阻害薬使用に伴う処方カスケード。

対象DB：CPRD

42. Association of osteoporosis treatment with risk of fracture, cardiovascular disease, and all-cause mortality in patients on maintenance dialysis: a retrospective database study using real-world data in Japan.

骨粗鬆症治療と骨折・心血管疾患・全死亡リスクの関連。

対象DB：DeSC